Dr Reddy’s Laboratories Gears Up for Q3 Reveal on 21st January; Check Key Expectations Here
Posted by : sachet | Tue Jan 20 2026
Click and Sign Up to Get Live Updates on Q3 Results
Dr Reddy’s Laboratories, one of the most significant Indian conglomerates, is set to announce its Q3 results for FY26 on 21st January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Dr Reddy’s Laboratories Q3 Results 2026 Preview
- Dr Reddy’s Laboratories’ revenue is expected to be in the range of ₹2,387 crore, a 15% YoY increase.
- Profit After Tax, or PAT, is projected to rise by 4% YoY.
- Dr Reddy’s Laboratories’ EBITDA is expected to rise to ₹23750 crore.
- Net profit is ₹3,080 crore, up 4% YoY
Dr Reddy’s Laboratories Share Performance
- Over the past six months, Dr Reddy’s Laboratories’ share price has grown by 5.71% to ₹1,187.10.
- Moreover, over the past year, the stock has increased by 8.90%.
- Despite this weak short-term performance, Dr Reddy’s Laboratories’ stock has delivered a financially sound 17.75% return over the past 5 years.
- As of 20th January 2026, the stock traded at ₹1,186.20 per share.
Key Factors to Watch for Dr Reddy’s Laboratories
- Performance in North America & Key Generics: Monitoring sales and pricing trends for high-value generics (such as Lenalidomide/Revlimid) is crucial, as pricing erosion and competition in the U.S. can significantly impact overall revenue and profitability.
- New Product Approvals & Pipeline Execution: The pace of ANDAs, biosimilars, and speciality product launches (e.g., Semaglutide and others) will drive future growth and help offset revenue decline from legacy products.
- Margins & Cost Management: Watch EBITDA and gross margin trends, as pricing pressure and SG&A and R&D cost increases can compress profitability even as revenues rise.
- Regulatory & Approval Environment: Timelines and outcomes of US FDA/EMA approvals materially affect drug launches, pipeline value, and long-term growth prospects — delays or compliance issues can directly hit earnings.
Final Thoughts
Dr Reddy’s Laboratories will announce its Q3 FY26 results on 21st January 2026. Analysts expect 15% YoY revenue growth, a 4% fall in PAT, and a 33% rise in EBITDA. Dr Reddy’s Laboratories focuses on expanding its global generics and speciality pharma portfolio through new product launches, strong R&D, and regulatory compliance to drive sustainable growth.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026
Best Stocks to Buy Today: Explore Best Stocks With Expected Trends
Milky Mist Dairy Foods IPO Details: Everything You Should Know about
Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?
Taurian MPS IPO GMP & Review: Should You Apply or Avoid?
Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?
Dev Accelerator IPO GMP & Review: Apply or Avoid?
Related Posts
Wendt India Gears Up for Q3 Reveal on 21st January; Check Key Expectations Here
UTI Asset Management Company Gears Up for Q3 Reveal on 21st January; Check Key Expectations Here
Supreme Industries Gears Up for Q3 Reveal on 21st January; Check Key Expectations Here
Thangamayil Jewellery Gears Up for Q3 Reveal on 21st January; Check Key Expectations Here
Tatva Chintan Pharma Chems Gears Up for Q3 Reveal on 21st January; Check Key Expectations Here
